Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group
Articolo
Data di Pubblicazione:
2018
Abstract:
Trabectedin is an alkylating drug with a unique mechanism of action causing single-strand and double-strand DNA breaks that activate DNA damage-response pathways. Based on our preclinical data, we hypothesised that poly(ADP-ribose) polymerase 1 (PARP1) inhibitors might be an ideal partner of trabectedin and aimed to assess the safety, identify the recommended phase 2 dose, and explore preliminary signs of activity of trabectedin and olaparib combination treatment in patients with bone and soft-tissue sarcoma.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Grignani, Giovanni; D'Ambrosio, Lorenzo; Pignochino, Ymera; Palmerini, Emanuela; Zucchetti, Massimo; Boccone, Paola; Aliberti, Sandra; Stacchiotti, Silvia; Bertulli, Rossella; Piana, Raimondo; Miano, Sara; Tolomeo, Francesco; Chiabotto, Giulia; Sangiolo, Dario; Pisacane, Alberto; Dei Tos, Angelo Paolo; Novara, Luca; Bartolini, Alice; Marchesi, Emanuela; D'Incalci, Maurizio; Bardelli, Alberto; Picci, Piero; Ferrari, Stefano; Aglietta, Massimo
Link alla scheda completa:
Pubblicato in: